Mami Ishikawa1, Takahiro Inoue1, Toshio Inui2, Daisuke Kuchiike3, Kentaro Kubo4, Yoshihiro Uto5, Takahito Nishikata6. 1. Frontiers of Innovative Research in Science and Technology (FIRST), Konan University, Kobe, Japan. 2. Department of Life System, Institute of Technology and Science, Graduate School, University of Tokushima, Tokushima, Japan Saisei Mirai Cell Processing Center, Osaka, Japan Kobe Saisei Mirai Clinic, Kobe, Japan Inui Immunotherapy Clinic, Osaka, Japan. 3. Department of Life System, Institute of Technology and Science, Graduate School, University of Tokushima, Tokushima, Japan Saisei Mirai Cell Processing Center, Osaka, Japan. 4. Saisei Mirai Cell Processing Center, Osaka, Japan. 5. Department of Life System, Institute of Technology and Science, Graduate School, University of Tokushima, Tokushima, Japan. 6. Frontiers of Innovative Research in Science and Technology (FIRST), Konan University, Kobe, Japan Frontier Institute for Biomolecular Engineering Research (FIBER), Konan University, Kobe, Japan nisikata@konan-u.ac.jp.
Abstract
BACKGROUND: Macrophages play important roles in antitumor immunity, and immunotherapy with the group-specific component protein-derived macrophage-activating factor (GcMAF) has been reported to be effective in patients with various types of cancers. However, in macrophage research, it is important to properly evaluate macrophage activity. MATERIALS AND METHODS: U937 macrophages were induced by 12-O-tetradecanoyl-13-phorbolacetate (TPA). The phagocytic activity of macrophages was evaluated as the internalized beads ratio. The MAF activity was assessed at 30 min after MAF addition as the activation ratio. RESULTS: We established a novel assay for phagocytic activities using differentiated U937 macrophages. CONCLUSION: The novel protocol was simple and rapid and was sensitive for GcMAF. This protocol should be useful not only for basic studies, such as those on molecular mechanisms underlying macrophage activation, but also for clinical studies, such as assessment of GcMAF activity prior to clinical use. Copyright
BACKGROUND: Macrophages play important roles in antitumor immunity, and immunotherapy with the group-specific component protein-derived macrophage-activating factor (GcMAF) has been reported to be effective in patients with various types of cancers. However, in macrophage research, it is important to properly evaluate macrophage activity. MATERIALS AND METHODS: U937 macrophages were induced by 12-O-tetradecanoyl-13-phorbolacetate (TPA). The phagocytic activity of macrophages was evaluated as the internalized beads ratio. The MAF activity was assessed at 30 min after MAF addition as the activation ratio. RESULTS: We established a novel assay for phagocytic activities using differentiated U937 macrophages. CONCLUSION: The novel protocol was simple and rapid and was sensitive for GcMAF. This protocol should be useful not only for basic studies, such as those on molecular mechanisms underlying macrophage activation, but also for clinical studies, such as assessment of GcMAF activity prior to clinical use. Copyright
Authors: Evgeniya V Dolgova; Svetlana S Kirikovich; Evgeniy V Levites; Vera S Ruzanova; Anastasia S Proskurina; Genrikh S Ritter; Oleg S Taranov; Nikolay A Varaksin; Tatiana G Ryabicheva; Olga Yu Leplina; Alexandr A Ostanin; Elena R Chernykh; Sergey S Bogachev Journal: Int J Mol Sci Date: 2022-07-22 Impact factor: 6.208